<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288585</url>
  </required_header>
  <id_info>
    <org_study_id>FDS-SCC-1552</org_study_id>
    <nct_id>NCT02288585</nct_id>
  </id_info>
  <brief_title>The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Effect of a Low-fat Spread Enriched With Plant Sterol Esters on the Blood Lipid Profile of Subjects With Established Type 2 Diabetes Mellitus and Subjects at High Risk of Developing Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unilever R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSIRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unilever R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomised, placebo-controlled, parallel group study with two intervention
      arms. The study will be conducted in 150 subjects and the primary objective is to show a
      fasting LDL-cholesterol and triglyceride lowering effect of plant sterols in subjects with
      established type 2 diabetes mellitus and subjects at high risk of developing type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aim of the study is to investigate the effect of plant sterols on fasting
      triglycerides and LDL-cholesterol concentrations.

      This study also aims to study the effect of plant sterols on fasting total cholesterol,
      HDL-cholesterol concentrations and Lipoprotein (a). Furthermore the effects of plant sterols
      on fasting blood glucose and insulin will be explored. At last, in a sub-group, at end of
      intervention the acute, chronic and acute upon chronic effect of plant sterols on
      postprandial blood lipids, glucose and insulin responses during a mixed meal challenge rich
      in fat and carbohydrates will be explored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TG concentrations</measure>
    <time_frame>At baseline (after 2 weeks run-in period) and after 6 weeks intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LDL-C</measure>
    <time_frame>At baseline (after 2 weeks run-in period) and after 6 weeks intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood lipids</measure>
    <time_frame>At baseline (after 2 weeks run-in period) and after 6 weeks intervention</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in blood glucose</measure>
    <time_frame>At baseline (after 2 weeks run-in period) and after 6 weeks intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in insulin</measure>
    <time_frame>At baseline (after 2 weeks run-in period) and after 6 weeks intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Acute, chronic and acute upon chronic effect on postprandial lipids, glucose and insulin</measure>
    <time_frame>At the end of intervention (after 6 weeks)</time_frame>
    <description>In a sub-group (n=48) of the population</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Advanced Glycation End products (AGEs)</measure>
    <time_frame>At baseline (after 2 weeks run-in period) and after 6 weeks intervention</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Vascular Diseases</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Plant sterols</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plant sterols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo product</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Plant sterols</intervention_name>
    <description>Plant sterols</description>
    <arm_group_label>Plant sterols</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo product</intervention_name>
    <description>Placebo product</description>
    <arm_group_label>Placebo product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Triglycerides &gt;150 mg/dL or 1.74 mmol/L

          -  LDL-cholesterol: Subjects at high risk for developing T2DM: 115-190 mg/dL or 2.95-4.94
             mmol/L. Subjects with established T2DM that are on statins: 85-190 mg/dL or 2.15-4.94
             mmol/L.

          -  HbA1c: Subjects at high risk for developing T2DM: &lt;6.50% or ≥ 48 mmol/mol. Subjects
             with established T2DM: ≤ 8.5% or ≤ 69 mmol/mol.

          -  BMI &gt; 20.0 kg/m2.

        Exclusion Criteria:

          -  Recently (within 1 year) diagnosed with cardiovascular event(s) (stroke, TIA, angina,
             myocardial infarction, heart failure), systemic inflammatory conditions

          -  Use of over-the-counter and prescribed medication which may interfere with study
             measurements (i.e. ezetimibe, fibrates and Niacin), to be judged by the principal
             investigator.

          -  Currently smoking or being a non-smoker for less than 6 months and reported use of any
             nicotine containing products in the 6 months prior to screening and/or during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manny Noakes</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSIRO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CSIRO</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSIRO, North Ryde</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plant sterols</keyword>
  <keyword>blood lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

